My valuation for NSP:Current Fair value: 26-28c per share 1,free...

My valuation for NSP:

Current Fair value: 26-28c per share

1,free carried 50% of NuSep’s Singapore plasma fractionation subsidiary, PrIME Biologics Pte Ltd (PrIME).

valuation: is S$30m (A$23m) or Circa 21c per share.

upside: AUD is much overvalued 15-25%, A$4.6m for 10% of PrIME will become floor price with project going forward.
Simple logic the later joining, the higher price to pay.

So 22-25c per share should be the correct valuation range for 50% of PrIME Biologics Pte Ltd.

2,Upcoming funding offer for SpermSep project.

Since NSP announced 2 month ago:"two offers the Company has received to fund the SpermSep project.NuSep is negotiating with these organisations and will report once it has finalised one or other of these projects."

I work out potential $3-5m funding will be received to support SpermSep project which as $60m-110m market target.

The funder should get 50% interest of SpermSep project, so the valuation for 50% of NSP's share is A$4m, circa 3.6c/share.

3, Gels, PROTEOIQ ,ProteomeSep, Didonostics products

Each above should be valued at $1m each, however I think with the gel sales growing but Didonostics products is promopting slowly, I give overall $2.2m valuation for these 4 categories. Circa 2c per share.

1+2+3= 23c+3.6c+2c = 28c per share.

Fair value with growth at logic:

4, Clearly above 1&2 is only based on the "investment value" like A$4.6m for 10% of PrIME, logically investors should expect at leat 100% return on their investment. NSP indicated NPV is circa $69m, IRR at 55%, with PrIME expanding, I am confident that NSP's remaining 50% will worth at least $40m-60m, and its holding would become a takeover target.

Hence, mid-term upside valuation potential for 50% of PrIME could be $50m, circa 46c per share.

5, DONOT FORGET:
"Further, this A$46m PrIME valuation is only for the therapeutic plasma application of NuSep’s PrIME technology and doesn’t include any other applications such as
recombinant therapeutics.”

Since NSP still hold 100% for any other applications such as recombinant therapeutics, I have to add another $10m for the valuation.circa another 9c per share.

6, Similar case and logic for SpermSep project, if investor paid $5m for 50%, expecting 10m return, we should add $10m for NSP's valuation as well. circa 9c per share.

4+5+6+3 =2.2c + 46c + 9c+ 9c = 66c per share.

This is only my personal, non professional valuation, please DYOR, but I believe we should get the similar figure if the broker's valuation report coming.

I hope you guys can also list your SP and valuation target.
Cheers